These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

561 related items for PubMed ID: 27736029

  • 41. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY, Wang DB, Song XQ, Wu YG, Chen Q, Zhao CL, Li JY, Cheng SH, Xu JY.
    Eur J Med Chem; 2018 Sep 05; 157():1292-1299. PubMed ID: 30195239
    [Abstract] [Full Text] [Related]

  • 42. New NSAID-Pt(IV) prodrugs to suppress metastasis and invasion of tumor cells and enhance anti-tumor effect in vitro and in vivo.
    Song XQ, Ma ZY, Wu YG, Dai ML, Wang DB, Xu JY, Liu Y.
    Eur J Med Chem; 2019 Apr 01; 167():377-387. PubMed ID: 30784875
    [Abstract] [Full Text] [Related]

  • 43. Photoinduced Reduction of Novel Dual-Action Riboplatin Pt(IV) Prodrug.
    Krasnovskaya OO, Akasov RA, Spector DV, Pavlov KG, Bubley AA, Kuzmin VA, Kostyukov AA, Khaydukov EV, Lopatukhina EV, Semkina AS, Vlasova KY, Sypalov SA, Erofeev AS, Gorelkin PV, Vaneev AN, Nikitina VN, Skvortsov DA, Ipatova DA, Mazur DM, Zyk NV, Sakharov DA, Majouga AG, Beloglazkina EK.
    ACS Appl Mater Interfaces; 2023 Mar 15; 15(10):12882-12894. PubMed ID: 36854172
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Platinum(IV)-nitroxyl complexes as possible candidates to circumvent cisplatin resistance in RT112 bladder cancer cells.
    Cetraz M, Sen V, Schoch S, Streule K, Golubev V, Hartwig A, Köberle B.
    Arch Toxicol; 2017 Feb 15; 91(2):785-797. PubMed ID: 27307157
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
    Xiao H, Yan L, Zhang Y, Qi R, Li W, Wang R, Liu S, Huang Y, Li Y, Jing X.
    Chem Commun (Camb); 2012 Nov 11; 48(87):10730-2. PubMed ID: 23012698
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF, Koberle B, Masters JR, Kelland LR.
    Br J Cancer; 1999 Dec 11; 81(8):1294-303. PubMed ID: 10604725
    [Abstract] [Full Text] [Related]

  • 56. Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.
    Ratzon E, Najajreh Y, Salem R, Khamaisie H, Ruthardt M, Mahajna J.
    BMC Cancer; 2016 Feb 23; 16():140. PubMed ID: 26906901
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Nano-assembly of ursolic acid with platinum prodrug overcomes multiple deactivation pathways in platinum-resistant ovarian cancer.
    Wang Y, Luo Z, Zhou D, Wang X, Chen J, Gong S, Yu Z.
    Biomater Sci; 2021 Jun 04; 9(11):4110-4119. PubMed ID: 33949442
    [Abstract] [Full Text] [Related]

  • 59. Anticancer metallodrugs: where is the next cisplatin?
    Hanif M, Hartinger CG.
    Future Med Chem; 2018 Mar 01; 10(6):615-617. PubMed ID: 29411994
    [Abstract] [Full Text] [Related]

  • 60. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
    Gentile F, Tuszynski JA, Barakat KH.
    J Mol Graph Model; 2016 Apr 01; 65():71-82. PubMed ID: 26939044
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.